Description: Zidebactam (WCK-5107; WCK5107) is a potent β-lactamase inhibitor and also a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL. It is one of the components ot WCK 5222 (Cefepime-Zidebactam) which is a bicyclo-acyl hydrazide β-lactam enhancer antibiotic with a dual action involving binding to Gram-negative bacterial PBP2 and β-lactamase inhibition. Cefepime/zidebactam demonstrated excellent activity against Enterobacteriaceae and P. aeruginosa, although activity was reduced in carbapenem-non-susceptible isolates. The activity against A. baumannii was reduced and studies examining the therapeutic efficacy in strains with high cefepime/zidebactam MICs are warranted.

References:

[1]. Sader HS, et al. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703.

[2]. Moya B, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent 'β-Lactam Enhancer' Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017 May 24;61(6)

Related CAS:1706777-46-9 (Sodium salt)

纯度：≥98%

CAS：1436861-97-0